Machine-learning derived identification of prognostic signature to forecast head and neck squamous cell carcinoma prognosis and drug response

被引:0
|
作者
Li, Sha-Zhou [1 ]
Sun, Hai-Ying [1 ]
Tian, Yuan [2 ]
Zhou, Liu-Qing [1 ]
Zhou, Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Hubei, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
machine learning; HNSCC; DEGs; tumor microenvironment; immunotherapy; CETUXIMAB; RECURRENT;
D O I
10.3389/fimmu.2024.1469895
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous malignancy is often associated with unfavorable prognosis. Due to its unique anatomical position and the absence of effective early inspection methods, surgical intervention alone is frequently inadequate for achieving complete remission. Therefore, the identification of reliable biomarker is crucial to enhance the accuracy of screening and treatment strategies for HNSCC.Method To develop and identify a machine learning-derived prognostic model (MLDPM) for HNSCC, ten machine learning algorithms, namely CoxBoost, elastic network (Enet), generalized boosted regression modeling (GBM), Lasso, Ridge, partial least squares regression for Cox (plsRcox), random survival forest (RSF), stepwise Cox, supervised principal components (SuperPC), and survival support vector machine (survival-SVM), along with 81 algorithm combinations were utilized. Time-dependent receiver operating characteristics (ROC) curves and Kaplan-Meier analysis can effectively assess the model's predictive performance. Validation was performed through a nomogram, calibration curves, univariate and multivariate Cox analysis. Further analyses included immunological profiling and gene set enrichment analyses (GSEA). Additionally, the prediction of 50% inhibitory concentration (IC50) of potential drugs between groups was determined.Results From analyses in the HNSCC tissues and normal tissues, we found 536 differentially expressed genes (DEGs). Subsequent univariate-cox regression analysis narrowed this list to 18 genes. A robust risk model, outperforming other clinical signatures, was then constructed using machine learning techniques. The MLDPM indicated that high-risk scores showed a greater propensity for immune escape and reduced survival rates. Dasatinib and 7 medicine showed the superior sensitivity to the high-risk NHSCC, which had potential to the clinical.Conclusions The construction of MLDPM effectively eliminated artificial bias by utilizing 101 algorithm combinations. This model demonstrated high accuracy in predicting HNSCC outcomes and has the potential to identify novel therapeutic targets for HNSCC patients, thus offering significant advancements in personalized treatment strategies.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Identification and validation of a novel tumor driver gene signature for diagnosis and prognosis of head and neck squamous cell carcinoma
    Liu, Shixian
    Liu, Weiwei
    Ding, Zhao
    Yang, Xue
    Jiang, Yuan
    Wu, Yu
    Liu, Yehai
    Wu, Jing
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [22] Identification of Interleukin-Related Genes Signature for Prognosis Prediction in Head and Neck Squamous Cell Carcinoma Patients
    Yang, Haojie
    Liu, Zihao
    Tan, Zicong
    Luo, Huimin
    Li, Qin
    Liu, Zhongqi
    Ji, Fengtao
    MOLECULAR CARCINOGENESIS, 2025,
  • [23] Identification of a Cancer Stem Cells Signature of Head and Neck Squamous Cell Carcinoma
    Wu, Zeng-Hong
    Li, Cheng
    Zhang, You-Jing
    Zhou, Wen
    FRONTIERS IN GENETICS, 2022, 13
  • [24] A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma
    Bai, Shuang
    Zhang, Ping
    Zhang, Jian-Cheng
    Shen, Jun
    Xiang, Xu
    Yan, Ying-Bin
    Xu, Zhen-Qi
    Zhang, Jun
    Long, Li
    Wang, Chao
    Shi, Ping
    Yang, Li
    Chen, Wei
    Liu, Hao
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (08): : 2581 - 2590
  • [25] A TRP Family Based Signature for Prognosis Prediction in Head and Neck Squamous Cell Carcinoma
    Pan, Fangfang
    Wang, Kai
    Zheng, Mengmeng
    Ren, Yuan
    Hao, Wenjuan
    Yan, Jiangyu
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [26] A six-mRNA signature model for the prognosis of head and neck squamous cell carcinoma
    Guo, Wenna
    Chen, Xijia
    Zhu, Liucun
    Wang, Qiang
    ONCOTARGET, 2017, 8 (55) : 94528 - 94538
  • [27] An aberrant DNA methylation signature for predicting the prognosis of head and neck squamous cell carcinoma
    Chen, Dayang
    Wang, Mengmeng
    Guo, Ying
    Wu, Wei
    Ji, Xiang
    Dou, Xiaowen
    Tang, Huamei
    Zong, Zengyan
    Zhang, Xiuming
    Xiong, Dan
    CANCER MEDICINE, 2021, 10 (17): : 5936 - 5947
  • [28] Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Signature in Head and Neck Squamous Cell Carcinoma
    Pan, Yunbao
    Liu, Guohong
    Wang, Dujuan
    Li, Yirong
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [29] Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma
    Shi, Hao
    Chen, Jian
    Li, Yuncheng
    Li, Guojun
    Zhong, Rong
    Du, Dandan
    Meng, Ruiwei
    Kong, Weijia
    Lu, Meixia
    ONCOTARGET, 2016, 7 (16) : 21579 - 21590
  • [30] A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma
    Li, Qilin
    Chen, Weimin
    Li, Qiuhui
    Mao, Jing
    Chen, Xin
    FRONTIERS IN IMMUNOLOGY, 2022, 13